<DOC>
	<DOCNO>NCT01567865</DOCNO>
	<brief_summary>The propose JEV05 study four-arm double-blind randomize controlled single center trial evaluate , examine post-vaccination seroprotection titer , lot-to-lot consistency three lot JE live attenuate SA 14-14-2 vaccine manufacture new GMP facility , establish non-inferiority new vaccine comparison single lot vaccine manufacture exist facility . The study enroll total 1,000 Bangladeshi infant age 10 12 month . In addition provide immunogenicity data , JEV05 provide local safety data JE live attenuate SA 14-14-2 vaccine among Bangladeshi child . This first step secure licensure life-saving vaccine Bangladesh well provide data support WHO prequalification JE live attenuate SA 14-14-2 vaccine .</brief_summary>
	<brief_title>Lot-to-lot Consistency Trial JE Live Attenuated SA 14-14-2 Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Infant 's parent ( ) legal guardian ( ) willing provide sign informed consent . Healthy infant age 10 12 month enrolment reside Matlab HDSS intervention area complete dos EPI immunization ( BCG , DPT , HBV , Hib , OPV measles ) least 4 week prior enrolment . Acute medical illness without fever within last 72 hour axillary temperature ( ≥ 37.5°C ) time vaccination . Use antibiotic antipyretic within last 72 hour prior enrolment . Severely moderately malnourished infant ( &lt; 3 Z score ) . History prematurity ( &lt; 36 week pregnancy ) . Underlying medical condition failure thrive , inborn error metabolism , bronchopulmonary dysplasia , major congenital abnormality require surgery chronic treatment . History serious chronic disease ( e.g. , cardiac , renal , neurologic , metabolic , rheumatologic , hematologic , bleed disorder ) . Known suspected impairment immunologic function . History document suspected encephalitis meningitis . History seizure , include history febrile seizure , neurologic disorder . History JE infection . Prior receipt JE vaccine . Received measles vaccine within 4 week prior , schedule receive vaccination , conduct trial . Prior anticipate receipt immune globulin blood product , injected oral corticosteroid immune modulator therapy within 6 week administration study vaccine . Serious adverse reaction ( e.g . urticaria , angioedema , shock , breathlessness follow vaccination life threaten condition ) previous EPI vaccine . Unable attend schedule visit comply study procedure . Enrolled another clinical trial involve therapy . Any condition opinion investigator , would pose health risk child , interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>10 Months</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>